Generic-drug approval growth doesn’t spark competition

The first three generics introduced make the biggest dent on prices. But the vast majority of generic-drug approvals from 2012 to 2017 were for the fourth, fifth, sixth or even later versions that minimally impact prices, according to a new report.

Read the full post at Modern Healthcare Breaking News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive